A detailed history of Assetmark, Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 11,805 shares of SRPT stock, worth $1.47 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,805
Previous 8,467 39.42%
Holding current value
$1.47 Million
Previous $1.1 Million 70.16%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$113.33 - $163.85 $378,295 - $546,931
3,338 Added 39.42%
11,805 $1.87 Million
Q1 2024

May 06, 2024

BUY
$93.7 - $141.53 $168,660 - $254,754
1,800 Added 27.0%
8,467 $1.1 Million
Q4 2023

Feb 09, 2024

BUY
$67.31 - $124.76 $191,900 - $355,690
2,851 Added 74.71%
6,667 $642,000
Q3 2023

Oct 27, 2023

BUY
$102.5 - $123.59 $57,195 - $68,963
558 Added 17.13%
3,816 $462,000
Q2 2023

Aug 11, 2023

BUY
$106.4 - $157.19 $346,651 - $512,125
3,258 New
3,258 $373,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.9B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.